High affinity human antibodies to human IL-4 receptor
The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.
1. A method of treating atopic dermatitis, said method comprising administering to a patient in need thereof an antibody or antigen-binding fragment thereof which specifically binds to a human interleukin-4 receptor, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region (HCVR) comprising the three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) from SEQ ID NO:162, and a light chain variable region (LCVR) comprising the three light chain CDRs (LCDR1, LCDR2 and LCDR3) from SEQ ID NO:164.
2. The method of claim 1 , wherein:
(a) the HCDR1 comprises SEQ ID NO:148;
(b) the HCDR2 comprises SEQ ID NO:150;
(c) the HCDR3 comprises SEQ ID NO:152;
(d) the LCDR1 comprises SEQ ID NO:156;
(e) the LCDR2 comprises SEQ ID NO:158; and
(f) the LCDR3 comprises SEQ ID NO:160.
3. The method of claim 2 , wherein the HCVR comprises SEQ ID NO:162.
4. The method of claim 2 , wherein the LCVR comprises SEQ ID NO:164.
5. The method of claim 2 , wherein the HCVR comprises SEQ ID NO:162 and the LCVR comprises SEQ ID NO:164.